Last updated September 9, 2026
Key finding
C-peptide AUC was 49% higher in the intervention group (P = 0.02).
This study evaluated the effects of ustekinumab in adolescents with recent-onset type 1 diabetes, finding significant improvements in C-peptide levels and reductions in specific T cell populations.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of ustekinumab in adolescents with recent-onset type 1 diabetes, finding significant improvements in C-peptide levels and reductions in specific T cell populations.
These findings suggest that ustekinumab could be a valuable treatment option for adolescents with recent-onset type 1 diabetes, potentially slowing disease progression and preserving insulin function, which is crucial for managing diabetes effectively.
Limited sample size may affect generalizability. Short duration of follow-up may not capture long-term effects. Unmeasured confounding factors could influence outcomes.
Published in
Publication details and source links for this paper.
Danijela T, Ashish M, Peter T, et al. A phase 2 randomized controlled trial of ustekinumab in adolescents with recent-onset type 1 diabetes. Nature Medicine. 2024;30(9):2657-2666. doi:10.1038/s41591-024-03115-2
C-peptide AUC increased by 49% in the intervention group (P = 0.02).
Reduction of T helper 17.1 cells correlated with preserved C-peptide levels (P = 0.04).
Significant decrease in IL-17A-secreting T cells (P = 0.0003).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Ustekinumab and C-peptide incremental area under the curve (iAUC), Cytokine production from T-helper 2 cells, IL-17A-secreting T cells.
This study contributes evidence to
Primary intervention
Ustekinumab
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
3
Evidence pairs
160
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Ustekinumab → C-peptide incremental area under the curve (iAUC)
Ustekinumab → C-peptide incremental area under the curve (iAUC)
Ustekinumab → Cytokine production from T-helper 2 cells
Ustekinumab → Cytokine production from T-helper 2 cells
Ustekinumab → IL-17A-secreting T cells
Ustekinumab → IL-17A-secreting T cells
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Ustekinumab and Cytokine production from T-helper 2 cells, Ustekinumab and IL-17A-secreting T cells.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Cytokine production from T-helper 2 cells
Measures Cytokine production from T-helper 2 cells as a key outcome.
All studies measuring IL-17A-secreting T cells
Measures IL-17A-secreting T cells as a key outcome.
All studies on Ustekinumab
Contributes to Ustekinumab evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Ustekinumab appears to improve c-peptide incremental area under the curve (IAUC).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
C-peptide incremental area under the curve (iAUC)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Ustekinumab appears to improve cytokine production from t-helper 2 cells.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Cytokine production from T-helper 2 cells
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Ustekinumab appears to improve il-17a-secreting t cells.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
IL-17A-secreting T cells
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
